Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:

Systolic, diastolic, mean blood pressure and pulse rate :-every 5 min during the titration phase-every 15 min up to the second hour treatment-every hour up to the 6th hour and every 3 hour during the rest of the treatment period. [ Time Frame: Systolic, diastolic, mean blood pressure and pulse rate :-every 5 min during the titration phase-every 15 min up to the second hour treatment-every hour up to the 6th hour and every 3 hour during the rest of the treatment period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

-maternal and foetal ultrasonography, biology and clinical assessment-type of delivery-post-partum bleeding-neo-natal evaluation by neonatologist during the first 48 hours of life [ Time Frame: During the first 48hour of life ] [ Designated as safety issue: Yes ]

acute eclampsia-requirement for other drugs with potential dangerous interactions with study drugs

participation to a therapeutic protocol within 6 months prior to the start of study

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00409253

Locations

France

Hôpital Saint-Jacques, CHU de Besançon

BESANçON, France, 25000

Maternité A. PINARD

Nancy, France, 54042

Sihcus-Cmco

Schiltigheim, France, 67303

Service d'Anesthésie et de Réanimation Médicale, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg